Treatment of hepatic or systemic FGF21 resistance maybe important in the treatment of NAFLD and other diseases, and this FGF21 resistance state can be ameliorated by certain therapies. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.